TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10861311

Group type: EXPERIMENTAL
Intervention: Diurnal cortisol slope
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cortisol rhythm
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: NK cell count and activity
Number of subjects: 104
Study: 8981290

Group type: EXPERIMENTAL
Intervention: Optimized peak power output (PPopt)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Corrected peak power output (PPcorr)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Optimized pedalling rate (RPMopt)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Corrected pedalling rate (RPMcorr)
Number of subjects: 37
Study: 1478168

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for one year)
Number of subjects: 98
Study: 6478732

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 21
Study: 30497962

Group type: EXPERIMENTAL
Intervention: OC-Sensor (Eiken Chemical, Tokyo, Japan)
Number of subjects: 21078

Group type: EXPERIMENTAL
Intervention: FOB-Gold (Sentinel Diagnostics, Milan, Italy)
Number of subjects: 21078

Group type: COMPARATOR
Intervention: Both FIT assays
Number of subjects: 21078
Study: 29262308

Group type: COMPARATOR
Intervention: Multiple‐Modality (M2) exercise
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Multiple‐Modality (M4) training
Number of subjects: 127
Study: 27179288

Group type: EXPERIMENTAL
Intervention: Telephone-based coached depression self-care intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Noncoached intervention
Number of subjects: 215
Study: 24768247

Group type: EXPERIMENTAL
Intervention: Dose-reduction-by-half group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Dose maintenance group
Number of subjects: 61
Study: 22892151

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 34
Study: 20819899

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (0.5 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other glucocorticoid doses and preparations
Number of subjects: 0
Study: 19116707

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, 18)
Number of subjects: 123
Study: 15829777

Group type: EXPERIMENTAL
Intervention: Self-monitoring approach (SMA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CR only)
Number of subjects: 45
Study: 12892188

Group type: EXPERIMENTAL
Intervention: PCL retained
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: PCL excised
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: PCL substituted with a posterior stabilised insert
Number of subjects: 211

Group type: COMPARATOR
Intervention: PCL released
Number of subjects: 211
Study: 11081531

Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone daily for 2 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 9002329

Group type: EXPERIMENTAL
Intervention: Tetravalent rhesus‐human reassortant rotavirus vaccine (4 x 10(4) plaque‐forming units/dose)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 1623865

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 154

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 154
Study: 3883593

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High oral doses of prednisone
Number of subjects: 50
Study: 30768394

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Community interventions (Control)
Number of subjects: 118
Study: 27977327

Group type: EXPERIMENTAL
Intervention: Relative right potentiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative left potentiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 27563602

Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation with IMF screws (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Erich arch bars (Group A)
Number of subjects: 60
Study: 24949989

Group type: EXPERIMENTAL
Intervention: Super-elastic heat-activated arch wires
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional multi-stranded stainless steel arch wires
Number of subjects: 82
Study: 22337714

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine and cyclophosphamide in combination with rituximab)
Number of subjects: 165

Group type: COMPARATOR
Intervention: FCCam (fludarabine and cyclophosphamide in combination with alemtuzumab)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 165

Group type: COMPARATOR
Intervention: FCCam
Number of subjects: 165
Study: 20363548

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 18503008

Group type: EXPERIMENTAL
Intervention: Standardized oral mixed meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intraperitoneal glucose infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls (comparison group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline plasma levels of PYY(1‐36)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline plasma levels of PYY(3‐36)
Number of subjects: 18
Study: 15816811

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a dosage of 1.6 IU/day (0.53 mg/day) for 6 months followed by 12 months of active GH treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after cessation of GH treatment
Number of subjects: 19
Study: 12442928

Group type: EXPERIMENTAL
Intervention: Milrinone (0.375 microg kg(‐1) min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine (0.2 microg kg(‐1) min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30
Study: 10368055

Group type: EXPERIMENTAL
Intervention: Type I bovine collagen barrier membrane
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PGA/PLA copolymer barrier membrane
Number of subjects: 19
Study: 8525418

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Thick Blood Film (TBF)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Quantitative Buffy Coat (QBC)
Number of subjects: 1095
Study: 2321293

Group type: EXPERIMENTAL
Intervention: Environmental room
Number of subjects: 292

Group type: COMPARATOR
Intervention: Traditional delivery room
Number of subjects: 292
Study: 227618

Group type: EXPERIMENTAL
Intervention: 4-month exercise program (3-4 weekly sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (maintained previous exercise habits)
Number of subjects: 100
Study: 31688649

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the knee extensors
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control leg (no stimulation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 13
Study: 30859637

Group type: EXPERIMENTAL
Intervention: Trunk training (12-week exercise program with trunk strengthening/motor control exercises)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Trunk training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Walking-balance training (control group)
Number of subjects: 64
Study: 27521821

Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg orally, 3 times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diosmin/Hesperidin (450/50 mg orally, twice daily)
Number of subjects: 30
Study: 26227554

Group type: EXPERIMENTAL
Intervention: Anxious Group
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 212
Study: 23296063

Group type: EXPERIMENTAL
Intervention: Paclitaxel/platinum chemotherapy followed by liposomal doxorubicin and gemcitabine (Group B)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Paclitaxel/platinum chemotherapy followed by platinum compounds, docetaxel and oral etoposide (Group A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Post-relapse treatment in Group B
Number of subjects: 113

Group type: COMPARATOR
Intervention: Post-relapse treatment in Group A
Number of subjects: 113
Study: 21970950

Group type: EXPERIMENTAL
Intervention: Bevacizumab (PRN dosing regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (monthly treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study: 18328464

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBTgsh)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWLgsh)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBTgsh) and Behavioral weight loss (BWLgsh)
Number of subjects: 75
Study: 16864762

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 10-session, manualized, individually administered regimen added to psychiatric consultation intervention
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard medical care augmented by a psychiatric consultation intervention (Control)
Number of subjects: 84
Study: 12638392

Group type: COMPARATOR
Intervention: Cetrorelix (CET) single doses (0.25, 0.5, or 1 mg) on cycle day 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) multiple doses from cycle day 3 to day 16
Number of subjects: 0
Study: 11032099

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional NSAIDs
Number of subjects: 0
Study: 9060527

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) and racemic leucovorin (d,l‐LV)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Fluorouracil (FU) combined with the pure l-isomer of leucovorin (l‐LV)
Number of subjects: 248
Study: 8181576

Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose recombinant interleukin-2 via central venous access (CVA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics via the CVA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Constant infusion of low dose streptokinase via the CVA
Number of subjects: 52
Study: 2535983

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1500 aPTT-U/24 h)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Unfractionated heparin (3 x 5000 IU/24 h)
Number of subjects: 404
Study: 786313

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 40
Study: 31529452

Group type: EXPERIMENTAL
Intervention: Cervical dilation ≥ 4 cm
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cervical effacement ≥ 75%
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Clinical and examination features (including parity and gestational age)
Number of subjects: 732
Study: 31369244

Group type: EXPERIMENTAL
Intervention: MgO thin film; film thickness of approximately 100 nm with calcination at 400‐600 °C in air
Number of subjects: 800

Group type: COMPARATOR
Intervention: Training data set
Number of subjects: 800

Group type: COMPARATOR
Intervention: Test data set
Number of subjects: 800
Study: 26507986

Group type: EXPERIMENTAL
Intervention: PEEK plate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 26
Study: 26457458

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 62
Study: 23562364

Group type: EXPERIMENTAL
Intervention: Low spinal BMD at baseline (BMD Z‐score ≤‐2 standard deviation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Baseline assessment for vertebral fractures (VF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment over 18 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quantitative techniques for vertebral height loss
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Assessment of fracture prediction factors
Number of subjects: 80
Study: 22417659

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7%
Number of subjects: 15

Group type: COMPARATOR
Intervention: CPAP at 10 cm H(2)O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPAP + HTS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Directed coughs (control)
Number of subjects: 15
Study: 19373126

Group type: EXPERIMENTAL
Intervention: Modified ETDRS-style (focal/grid) photocoagulation
Number of subjects: 22
Study: 17509808

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study: 15188160

Group type: EXPERIMENTAL
Intervention: FOBT screening
Number of subjects: 91999

Group type: EXPERIMENTAL
Intervention: FOBT screening (participants who participated at least once)
Number of subjects: 91999

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 91999
Study: 11397602

Group type: EXPERIMENTAL
Intervention: Three pain assessment instruments (visual analog scale, behavior (faces) scale, pain descriptive scale)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Question 'Do you have pain?'
Number of subjects: 305
Study: 9194109

Group type: EXPERIMENTAL
Intervention: Bio-Hep-B (2.5 micrograms/dose)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Engerix-B (10 micrograms/dose)
Number of subjects: 205
Study: 1357927

Group type: EXPERIMENTAL
Intervention: 100 Hz cranial TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5 Hz cranial TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2000 Hz cranial TENS
Number of subjects: 90
Study: 3912647

Group type: EXPERIMENTAL
Intervention: 800 mg of arginine pyroglutamate three times a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 90
Study: 30535959

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablet (test product)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ZYTIGA® (250 mg, reference product)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 32
Study: 29171107

Group type: EXPERIMENTAL
Intervention: Self-report on the Pittsburgh Sleep Quality Index for the previous month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report on the recording night
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actigraphic measures on the recording night
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diary-reported number of awakenings
Number of subjects: 0
Study: 24224856

Group type: EXPERIMENTAL
Intervention: Single-curved instruments
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Articulating instruments
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional straight instruments
Number of subjects: 24

Group type: COMPARATOR
Intervention: Double-curved instruments
Number of subjects: 24
Study: 23155130

Group type: EXPERIMENTAL
Intervention: Upwards stripping of great saphenous vein (GSV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Downwards stripping of great saphenous vein (GSV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions (upwards and downwards stripping)
Number of subjects: 50
Study: 23662513

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 162
Study: 21059213

Group type: EXPERIMENTAL
Intervention: MPH1 (7.5 mg Isoleucine‐Proline‐Proline)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MPH2 (6.6 mg Methionine‐Alanine‐Proline, 2.3 mg Leucine‐Proline‐Proline, 1.8 mg IPP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (containing cellulose)
Number of subjects: 70
Study: 17414391

Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Sibling pairs
Number of subjects: 248
Study: 15857459

Group type: EXPERIMENTAL
Intervention: Aloe vera gel applied twice daily for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 41
Study: 12187617

Group type: EXPERIMENTAL
Intervention: POST - Predefined formula beverage with added carbohydrate following exercise bouts on days 1, 3, 4, and 6
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON - Placebo beverage consumed following exercise bouts on days 1, 3, 4, and 6
Number of subjects: 10
Study: 9618626

Group type: EXPERIMENTAL
Intervention: Community-based prevention program
Number of subjects: 0
Study: 7740405

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy for high-grade soft-tissue sarcomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant induction chemotherapy, regional perfusion with cytostatics (± hyperthermia), externally applicated deep regional tumor hyperthermia with systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncontrolled adjuvant treatment of soft-tissue sarcomas with cytostatic drugs
Number of subjects: 0
Study: 2179591

Group type: EXPERIMENTAL
Intervention: Abdominal injection of insulin for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rotating injection among arms, abdomen, and thighs for 3 days
Number of subjects: 12
Study: 6102456

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine administered intravenously
Number of subjects: 12
Study: 30211831

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Sulfated Dextran (LMW-DS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 24
Study: 27821644

Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg + allopurinol
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg + allopurinol
Number of subjects: 610

Group type: COMPARATOR
Intervention: Allopurinol alone
Number of subjects: 610
Study: 25175734

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 24038026

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 21174586

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 400 IU natural vitamin E (RRR α tocopherol) daily from the second trimester until delivery
Number of subjects: 50

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 50
Study: 19247887

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revised version of London's standard
Number of subjects: 0
Study: 17892989

Group type: COMPARATOR
Intervention: Direct stenting guided with quantitative coronary angiography (group 1)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Direct stenting guided with IVUS (group 2)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Optimal balloon angioplasty guided with IVUS (group 3)
Number of subjects: 259
Study: 15457418

Group type: EXPERIMENTAL
Intervention: Metal-on-metal group (95 patients)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Metal-on-polyethylene group (76 patients)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study: 11578890

Group type: EXPERIMENTAL
Intervention: 2 mg/kg with 4% lidocaine (Group I; n = 15)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 4 mL with saline (Group 2; n = 16)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nothing (Control; n = 15)
Number of subjects: 46
Study: 9542554

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with sufentanil 10 micrograms (LD)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: bupivacaine 0.25% with adrenaline (HD)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with sufentanil (LD)
Number of subjects: 1000
Study: 7842911

Group type: EXPERIMENTAL
Intervention: GTW+CSA+Pred
Number of subjects: 172

Group type: COMPARATOR
Intervention: Aza+CSA+Pred
Number of subjects: 172
Study: 2970361

Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 0
Study: 31294630

Group type: EXPERIMENTAL
Intervention: On-demand HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 83
Study: 31650914

Group type: EXPERIMENTAL
Intervention: Knotless suture bridge technique (group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Medial knotted suture bridge technique (group A)
Number of subjects: 121
Study: 28207654

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 47
Study: 25277645

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate and metronidazole (2-antimicrobial group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (control group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both antibiotics continued (2-antimicrobial group)
Number of subjects: 60
Study: 23489381

Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion
Number of subjects: 107
Study: 20061435

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg/d)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 274
Study: 18550177

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 477
Study: 15665210

Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (normal training routine)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme aimed at players with previous ankle sprains
Number of subjects: 116
Study: 12947995

Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0